MACROGENICS, INC. Other Non-Current Assets
MACROGENICS, INC. (MGNX) had Other Non-Current Assets of $195.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OtherAssetsNoncurrent · last filed 2026-08-14
- 2026-06-30: Other Assets, Noncurrent $195.00K.
- 2026-03-31: Other Assets, Noncurrent $1.38M.
- 2025-12-31: Other Assets, Noncurrent $207.00K; Other Assets, Noncurrent as first filed $1.39M.
- 2025-09-30: Other Assets, Noncurrent $1.39M.
| Period end | Other Assets, Noncurrent | Other Assets, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $195.00K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $1.38M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $207.00K 10-Q · filed 2026-08-14 | $1.39M 10-K · filed 2026-03-09 |
| 2025-09-30 | $1.39M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $1.40M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $1.49M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $1.56M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $1.19M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $1.19M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $1.19M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $1.39M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $1.39M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $1.39M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $1.38M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $1.38M 10-K · filed 2024-03-07 | |
| 2022-09-30 | $15.54M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $16.39M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $17.21M 10-Q · filed 2022-05-03 | |
| 2021-12-31 | $1.40M 10-K · filed 2023-03-15 | $18.01M 10-K · filed 2022-02-24 |
| 2021-09-30 | $18.78M 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $19.52M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $20.25M 10-Q · filed 2021-04-29 | |
| 2020-12-31 | $23.92M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $22.89M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $23.51M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $23.81M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $24.50M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $25.25M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $43.78M 10-Q · filed 2019-07-31 | |
| 2019-03-31 | $24.79M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $6.29M 10-K · filed 2020-02-25 | |
| 2018-09-30 | $11.06M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $7.35M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $1.60M 10-Q · filed 2018-05-07 | |
| 2017-12-31 | $1.60M 10-K · filed 2019-02-26 | |
| 2017-09-30 | $1.54M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $1.55M 10-Q · filed 2017-08-02 | |
| 2017-03-31 | $1.36M 10-Q · filed 2017-05-03 | |
| 2016-12-31 | $1.37M 10-K · filed 2018-02-27 | |
| 2016-09-30 | $2.10M 10-Q · filed 2016-11-02 | |
| 2016-06-30 | $2.11M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | $2.04M 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $2.04M 10-K · filed 2017-02-28 | |
| 2015-09-30 | $2.06M 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $2.06M 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $2.06M 10-Q · filed 2015-05-06 | |
| 2014-12-31 | $2.06M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $733.00K 10-Q · filed 2014-11-12 | |
| 2014-06-30 | $1.11M 10-Q · filed 2014-08-05 | |
| 2014-03-31 | $2.28M 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $885.00K 10-K · filed 2015-03-03 | $885.17K 10-K · filed 2014-03-20 |
| 2013-09-30 | $147.25K 10-Q · filed 2013-11-12 | |
| 2012-12-31 | $147.25K 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |